People suffering from small cell lung cancer haven’t had many treatment options over the past couple of decades. And while we applaud the recent advancements in immunotherapy like atezolizumab, durvalumab, and tarlatamab, as well as the chemotherapy drug lurbinectedin, there is still much work to do.

Decentralized Clinical Trials (DCTs) represent a paradigm shift in clinical research, moving away from the traditional hospital-centric model. By incorporating remote data collection, telehealth consultations, and home health visits, DCTs leverage technology to enhance flexibility and improve patient experience.

There is an urgent need for research into the relationship between LEMS and small cell lung cancer. Understanding this association can better facilitate advancements in medical research and treatments.